Data Sheet (Cat.No.T64133L)



Laniquidar TFA

Chemical Properties


CAS No.:

Formula: C39H37F3N4O5

Molecular Weight: 698.73

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

| Description | Laniquidar TFA (R101933) is a novel orally available non-competitive P-glycoprotein (P-gp) inhibitor with an IC50 value of 0.51 μ M.Laniquidar has limited bioavailability and can be used to modulate the multidrug resistance transporter.Laniquidar can be used for the study of AML and myelodysplastic syndrome (MDS). Laniquidar is used to study acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). |
|---------------|---|
| Targets(IC50) | P-gp |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg | |
|-------|-----------|-----------|------------|--|
| 1 mM | 1.4312 mL | 7.1558 mL | 14.3117 mL | |
| 5 mM | 0.2862 mL | 1.4312 mL | 2.8623 mL | |
| 10 mM | 0.1431 mL | 0.7156 mL | 1.4312 mL | |
| 50 mM | 0.0286 mL | 0.1431 mL | 0.2862 mL | |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Luurtsema G, et al. Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl Med Biol. 2009 Aug;36(6):643-9.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 1 of 1 www.targetmol.com